Status:
RECRUITING
Point of Care Testing for Presence of Current and or Previous T. Gondii Infection
Lead Sponsor:
University of Chicago
Conditions:
Toxoplasma Infections
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
This is part of a feasibility study to compare the predicate standard FDA cleared test for serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by LD Bio Diagnostic. The specificity and se...
Detailed Description
This study will determine the feasibility of using the point of care Toxoplasma ICT IgG-IgM BK test produced by LD Bio Diagnostic to detect Toxoplasma gondii in clinical settings. The result of testin...
Eligibility Criteria
Inclusion
- any adult who is willing to participate in the study
Exclusion
- pregnant women who are in their 17-27 weeks of gestation.
Key Trial Info
Start Date :
August 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 20 2026
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT04474132
Start Date
August 13 2020
End Date
August 20 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637